Peter D. Suzdak, CEO of Rexahn Pharmaceuticals, said his company aims to make cancer therapies that “eliminate the collateral damage” caused by other drugs on the market.
from https://www.bizjournals.com/baltimore/news/2018/05/15/md-biotech-firm-nears-market-with-two-cancer-drugs.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/173932368452
No comments:
Post a Comment